SCHEMBL4433133

SCHEMBL4433133

Cn1cc(-c2cc(F)cc(CC(=O)O)c2)cn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 4/20 0.48
CFD P00746 1/20 0.46
ERN1 O75460 2/20 0.45
PTGDR2 Q9Y5Y4 1/20 0.45
LOXL2 Q9Y4K0 2/20 0.43
MAOA P21397 1/20 0.43
KCNH2 Q12809 1/20 0.43
AOC3 Q16853 1/20 0.43
PIM1 P11309 1/20 0.42
PIM2 Q9P1W9 1/20 0.42
NTRK1 P04629 1/20 0.41
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41
RXRG P48443 1/20 0.41
BRD4 O60885 1/20 0.41
CREBBP Q92793 1/20 0.41
PDPK1 O15530 1/20 0.40
RPS6KB1 P23443 1/20 0.40
WNT1 P04628 1/20 0.40
GSK3B P49841 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1560060 0.85 MET (0.48) METCFDERN1LOXL2MAOA
SCHEMBL30767777 0.83 RXRA (0.52) CFDLOXL2RXRARXRBRXRG
SCHEMBL30767752 0.81 RXRA (0.45) METCFDPTGDR2RXRARXRB
SCHEMBL30767754 0.81 RXRA (0.39) METCFDPTGDR2KCNH2RXRA
SCHEMBL17794666 0.81 KCNH2 (0.46) METERN1LOXL2MAOAKCNH2
SCHEMBL1558826 0.80 MET (0.42) METCFDERN1PTGDR2LOXL2
SCHEMBL30767742 0.80 MKNK1 (0.53) METCFDPTGDR2PIM1PIM2
SCHEMBL1560003 0.80 MET (0.45) METERN1LOXL2MAOAKCNH2
SCHEMBL21174253 0.80 LOXL2 (0.52) METERN1LOXL2MAOAKCNH2
SCHEMBL30767760 0.79 PTGDR2 (0.45) PTGDR2RXRARXRBRXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024014851-A1 NOVEL PURINE DERIVATIVE COMPOUNDS AS HIF-1 PROTEIN INHIBITOR 주식회사 넥스트젠바이오사이언스 2024-01-18 WO disclosed
US-10800754-B2 Heterocyclic amide compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-10-13 US disclosed
EP-3514150-A1 HETEROCYCLIC AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2019-07-24 EP disclosed
EP-2303873-A1 BENZOXAZINONE DERIVATIVES ACTING AS BETA2-ADRENORECEPTOR AGONIST FOR THE TREATMENT OF RESPIRATORY DISORDERS AstraZeneca AB (SE) 2011-04-06 EP disclosed
WO-2009154557-A1 BENZOXAZINONE DERIVATIVES ACTING AS BETA2-ADRENORECEPTOR AGONIST FOR THE TREATMENT OF RESPIRATORY DISORDERS ASTRAZENECA AB (SE) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10800754-B2 Heterocyclic amide compound PRSS8, PRSS1, PRSS2 MET 4168/4885CFD 4738/4885ERN1 838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.